Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
biotechnology: Archive
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
by Zacks Equity Research
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.
BMYPositive Net Change ONCYNegative Net Change FATEPositive Net Change OMGANegative Net Change
biotechnology biotechs earnings pharmaceuticals
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
by Zacks Equity Research
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
ADMAPositive Net Change FGENNegative Net Change IMVTNegative Net Change ANVSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
by Zacks Equity Research
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
VRTXPositive Net Change ADMAPositive Net Change FGENNegative Net Change ANVSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
by Zacks Equity Research
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
BPTHNegative Net Change ADMAPositive Net Change FGENNegative Net Change ANVSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
by Zacks Equity Research
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
RHHBYPositive Net Change LGNDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change
biotechnology medical pharmaceuticals
Novartis (NVS) to Report Q1 Earnings: What to Expect?
by Ekta Bagri
Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.
NVSPositive Net Change BMRNNegative Net Change ONCYNegative Net Change FATEPositive Net Change
biotechnology earnings medical pharmaceuticals
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
by Zacks Equity Research
Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
REGNPositive Net Change GSKPositive Net Change ITCINegative Net Change SAGENegative Net Change NMRANegative Net Change
biotechnology biotechs pharmaceuticals
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
by Zacks Equity Research
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
ADMAPositive Net Change FGENNegative Net Change DMACNegative Net Change ANVSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
by Zacks Equity Research
Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
ITCINegative Net Change ADMAPositive Net Change FGENNegative Net Change ANVSNegative Net Change
biotechnology biotechs medical pharmaceuticals
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
by Zacks Equity Research
bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.
VRTXPositive Net Change BLUENegative Net Change ADMAPositive Net Change CRSPNegative Net Change
biotechnology biotechs pharmaceuticals
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
by Zacks Equity Research
Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.
RARENegative Net Change ADMAPositive Net Change FGENNegative Net Change ANVSNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
After Golden Cross, CuriosityStream Inc. (CURI)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
CURINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
by Zacks Equity Research
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
GILDPositive Net Change FGENNegative Net Change ANVSNegative Net Change XLONegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
by Zacks Equity Research
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
NVSPositive Net Change ANIPPositive Net Change ADMAPositive Net Change CALTPositive Net Change
biotechnology pharmaceuticals
Adaptimmune (ADAP) Down on End of Collaboration With Roche
by Zacks Equity Research
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
GSKPositive Net Change RHHBYPositive Net Change PSTXNegative Net Change ADAPNegative Net Change
biotechnology biotechs pharmaceuticals
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
by Zacks Equity Research
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
RHHBYPositive Net Change BMYPositive Net Change ALXONegative Net Change NRIXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
by Zacks Equity Research
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
NVSPositive Net Change MORPositive Net Change ARVNNegative Net Change
biotechnology medical pharmaceuticals
Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
by Zacks Equity Research
The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.
REGNPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change ADMAPositive Net Change
biotechnology biotechs medical pharmaceuticals
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
by Zacks Equity Research
RallyBio (RLYB) gains 83% after announcing a collaboration deal with J&J to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of $6.6 million from the latter.
JNJPositive Net Change FGENNegative Net Change ANVSNegative Net Change RLYBNegative Net Change
biotechnology biotechs medical pharmaceuticals
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
by Zacks Equity Research
Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.
ADMAPositive Net Change FGENNegative Net Change ANVSNegative Net Change CADLNegative Net Change
biotechnology biotechs medical pharmaceuticals
SNDL Inc. (SNDL) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SNDLNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
by Zacks Equity Research
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
BMYPositive Net Change MRNANegative Net Change SYRSNegative Net Change AMLXNegative Net Change TSVTNegative Net Change
biotechnology biotechs
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
DTILNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novartis (NVS) to Undertake Job Cuts in Development Department
by Zacks Equity Research
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
NVSPositive Net Change INCYNegative Net Change MORPositive Net Change
biotechnology biotechs medical pharmaceuticals
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
by Zacks Equity Research
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
RHHBYPositive Net Change BMYPositive Net Change ALXONegative Net Change NRIXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals